Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 753-760

  Takeda, Koji ^a   Hida, Toyoaki ^a   Sato, Tosiya ^a   Ando, Masahiko ^a   Seto, Takashi ^a   Satouchi, Miyako ^a   Ichinose, Yukito ^a   Katakami, Nobuyuki ^a   Yamamoto, Nobuyuki ^a   Kudoh, Shinzoh ^a   Sasaki, Jiichiro ^a   Matsui, Kaoru ^a   Takayama, Koichi ^a   Kashii, Tatsuhiko ^a   Iwamoto, Yasuo ^a   Sawa, Toshiyuki ^a   Okamoto, Isamu ^a   Kurata, Takayasu ^a   Nakagawa, Kazuhiko ^a   Fukuoka, Masahiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; ELECTROCARDIOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; INTERSTITIAL LUNG DISEASE; JAPANESE; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SCORING SYSTEM; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ASIAN; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; ETHNOLOGY; JAPAN; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATIENT SELECTION; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649203360     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.3445     Document Type: Article

References (27)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533-543, 2001
2. Dancey J, Shepherd FA, Gralla RJ, et al: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 43:183-194, 2004 (Pubitemid 38114747)
3. Socinski MA, Morris DE, Masters GA, et al: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123:226S-243S, 2003 (suppl 1)
4. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
5. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3553, 2008
6. Jorissen RN, Walker F, Pouliot N, et al: Epidermal growth factor receptor: Mechanisms of activation and signaling. Exp Cell Res 284:31-53, 2003 (Pubitemid 36331965)
7. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
8. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
9. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004 (Pubitemid 41103588)
10. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004 (Pubitemid 41103589)
11. Ando M, Okamoto I, Yamamoto N, et al: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549-2556, 2006 (Pubitemid 46630633)
12. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with post-operative recurrence. J Clin Oncol 23:2513-2520, 2005 (Pubitemid 47050841)
13. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203, 2004
14. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-1173, 2005 (Pubitemid 40175767)
15. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan. Ann Oncol 18:317-323, 2007 (Pubitemid 46323100)
16. Kubota K, Watanabe K, Kunitoh H, et al: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254-261, 2004
17. National Cancer Institute: National Cancer Institute Common Toxicity Criteria version 2.0. http://ctep.cancer.gov/forms/CTCv20-4-30-992.pdf
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
19. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
20. Brodowicz T, Krzakowski M, Zwitter M, et al: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 52:155-163, 2006
21. Fidias P, Dakhil S, Lyss A, et al: Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: Updated report with survival. J Clin Oncol 27:591-598, 2009
22. Belani CP, Brodowicz T, Ciuleanu T, et al: Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27:407s, 2009 (suppl; abstr CRA8000)
23. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27:407s, 2009 (suppl; abstr 8001)
24. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
25. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
26. Yang CH, Yu CJ, Shih JY, et al: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26:2745-2753, 2008
27. Tamura K, Okamoto I, Kashii T, et al: Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98:907-914, 2008